These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15350601)

  • 1. Chemotherapy targeted to cancers through tumoral hormone receptors.
    Schally AV; Nagy A
    Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
    Schally AV
    An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamic hormones and cancer.
    Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G
    Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
    Schally AV; Nagy A
    Eur J Endocrinol; 1999 Jul; 141(1):1-14. PubMed ID: 10407215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.
    Schally AV; Engel JB; Emons G; Block NL; Pinski J
    Curr Drug Deliv; 2011 Jan; 8(1):11-25. PubMed ID: 21034424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin.
    Schally AV; Nagy A
    Life Sci; 2003 Apr; 72(21):2305-20. PubMed ID: 12639697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to the therapy of various tumors based on peptide analogues.
    Schally AV
    Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K; Schally AV; Halmos G
    Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A; Schally AV; Djavan B
    Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
    Nagy A; Schally AV
    Curr Pharm Des; 2005; 11(9):1167-80. PubMed ID: 15853664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro.
    Krebs LJ; Wang X; Nagy A; Schally AV; Prasad PN; Liebow C
    Int J Oncol; 2002 Dec; 21(6):1325-9. PubMed ID: 12429984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
    Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
    Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers.
    Szepeshazi K; Block NL; Schally AV
    Horm Mol Biol Clin Investig; 2010 Jan; 1(3):103-10. PubMed ID: 25961976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in the study of small peptides in targeted drug delivery system].
    Sun Y; Wang C
    Yao Xue Xue Bao; 2008 Oct; 43(10):992-6. PubMed ID: 19127861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.